Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc. on April 22, 2024. As part of the transaction, Weil, Gotshal & Manges LLP is acting as legal advisor to Eli Lilly and Company. Centerview Partners LLC is acting as financial advisor, and Sullivan & Cromwell LLP as legal advisor to Nexus Pharmaceuticals, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
735 USD | -2.77% | +1.39% | +26.08% |
May. 03 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
May. 03 | News Highlights : Top Company News of the Day - Friday at 7 PM ET | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B | |
+8.08% | 149B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly and Company entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc.